Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

New research links ultra-processed food intake to higher psoriasis risk, even after accounting for genetics, BMI, and lifestyle, highlighting the potential of dietary changes in preventing chronic ...

Psoriasis significantly impacts psychological and social well-being, with high rates of depression, anxiety, and suicidal ideation among patients. Effective management requires a holistic, patient ...

Results showed 66% of patients treated with icotrokinra achieved an ss-IGA score of 0/1 and 77% achieved a sPGA-G score of 0/1, compared with 11% and 21% receiving placebo, respectively, at week 16.

Patanjali Ayurved's research, published in the Journal of Inflammation Research, reveals promising results for their Ayurvedic treatment of psoriasis using Psorogrit tablets and Divya Taila.

Once-daily 0.3% topical roflumilast foam significantly reduced severity in patients with psoriasis of the scalp and body over 8 weeks, with a favorable safety profile. “Use of roflumilast foam ...

If you have psoriasis, a chronic skin condition caused by an overactive immune system, you may have patches of red, inflamed, or painful, dead skin buildup all over your body. Psoriasis may also ...

In 2022, a drug called deucravacitinib was approved by the U.S. Food and Drug Administration to treat psoriasis. This medication targets TYK2 in a way that stops its ability to relay harmful ...

Psoriasis -- the chronic condition that causes red, scaly, itchy patches on your skin -- comes and goes. Your psoriasis can change in how serious it is and how often you have symptoms. Psoriasis ...

INDIANAPOLIS (WISH) — A drug already approved by the U.S. Food and Drug Administration to treat psoriasis could offer new hope for people with Type 1 diabetes, according to a new study co-led by ...

The FDA slapped a clinical hold on a phase 1b plaque psoriasis trial after testicular toxicity was reported in dogs from a nonclinical test. Research into the use of BET inhibitors to treat cancer ...